141 related articles for article (PubMed ID: 20577127)
1. Differential effects of acute and sustained cyclosporine and tacrolimus on sympathetic nerve activity.
Klein IH; Abrahams AC; van Ede T; Oey PL; Ligtenberg G; Blankestijn PJ
J Hypertens; 2010 Sep; 28(9):1928-34. PubMed ID: 20577127
[TBL] [Abstract][Full Text] [Related]
2. Sympathoexcitation in calcineurin inhibitor-induced hypertension: villain or innocent bystander?
Schlaich MP; Grassi G
J Hypertens; 2010 Sep; 28(9):1809-10. PubMed ID: 20699713
[No Abstract] [Full Text] [Related]
3. Salt supresses baseline muscle sympathetic nerve activity in salt-sensitive and salt-resistant hypertensives.
Abrahão SB; Tinucci T; Santello JL; Mion D
J Hum Hypertens; 2002 Dec; 16(12):843-50. PubMed ID: 12522465
[TBL] [Abstract][Full Text] [Related]
4. Cyclosporine-induced hypertension: evidence for maintained baroreflex circulatory control.
Lucini D; Milani RV; Ventura HO; Mehra MR; Messerli FH; Murgo JP; Regenstein F; Copley B; Malliani A; Pagani M
J Heart Lung Transplant; 1997 Jun; 16(6):615-20. PubMed ID: 9229291
[TBL] [Abstract][Full Text] [Related]
5. Sirolimus conversion for renal preservation in liver transplantation: not so fast.
Jensen GS; Wiseman A; Trotter JF
Liver Transpl; 2008 May; 14(5):601-3. PubMed ID: 18433068
[No Abstract] [Full Text] [Related]
6. Increased adherence after switch from twice daily calcineurin inhibitor based treatment to once daily modified released tacrolimus in heart transplantation: a pre-experimental study.
Doesch AO; Mueller S; Konstandin M; Celik S; Erbel C; Kristen A; Frankenstein L; Koch A; Dengler TJ; Ehlermann P; Zugck C; De Geest S; Katus HA
Transplant Proc; 2010 Dec; 42(10):4238-42. PubMed ID: 21168673
[TBL] [Abstract][Full Text] [Related]
7. What does the CONVERT trial really tell us about conversion from calcineurin inhibitors to sirolimus?
Hanto DW; Chudzinski R
Transplantation; 2009 Jan; 87(2):164-5. PubMed ID: 19155968
[No Abstract] [Full Text] [Related]
8. Calcineurin inhibitors and post-transplant weight gain.
Ersoy A; Baran B; Ersoy C; Kahvecioglu S; Akdag I
Nephrology (Carlton); 2008 Oct; 13(5):433-9. PubMed ID: 18331443
[TBL] [Abstract][Full Text] [Related]
9. Target blood concentrations of CYA and tacrolimus in randomized controlled trials for the prevention of acute GVHD after hematopoietic SCT.
Oshima K; Sato M; Terasako K; Kimura S; Okuda S; Kako S; Kanda Y
Bone Marrow Transplant; 2010 Apr; 45(4):781-2. PubMed ID: 19701249
[No Abstract] [Full Text] [Related]
10. Sirolimus in liver transplant recipients with renal dysfunction offers no advantage over low-dose calcineurin inhibitor regimens.
DuBay D; Smith RJ; Qiu KG; Levy GA; Lilly L; Therapondos G
Liver Transpl; 2008 May; 14(5):651-9. PubMed ID: 18433069
[TBL] [Abstract][Full Text] [Related]
11. Calcineurin inhibitors in heart transplantation.
Keogh A
J Heart Lung Transplant; 2004 May; 23(5 Suppl):S202-6. PubMed ID: 15093806
[TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamic analysis of tacrolimus and cyclosporine in living-donor liver transplant patients.
Fukudo M; Yano I; Masuda S; Fukatsu S; Katsura T; Ogura Y; Oike F; Takada Y; Tanaka K; Inui K
Clin Pharmacol Ther; 2005 Aug; 78(2):168-81. PubMed ID: 16084851
[TBL] [Abstract][Full Text] [Related]
13. Randomized controlled study comparing reduced calcineurin inhibitors exposure versus standard cyclosporine-based immunosuppression.
Hernández D; Miquel R; Porrini E; Fernández A; González-Posada JM; Hortal L; Checa MD; Rodríguez A; García JJ; Rufino M; Torres A
Transplantation; 2007 Sep; 84(6):706-14. PubMed ID: 17893603
[TBL] [Abstract][Full Text] [Related]
14. FK506 effectiveness in reducing acute rejection after heart transplantation: a prospective randomized study.
Rinaldi M; Pellegrini C; Martinelli L; Goggi C; Gavazzi A; Campana C; Arbustini E; Grossi P; Regazzi M; Ippoliti G; Vigano M
J Heart Lung Transplant; 1997 Oct; 16(10):1001-10. PubMed ID: 9361242
[TBL] [Abstract][Full Text] [Related]
15. Conversion to sirolimus with calcineurin inhibitor elimination vs. dose minimization and renal outcome in heart and lung transplant recipients.
Demirjian S; Stephany B; Abu Romeh IS; Boumitri M; Yamani MH; Poggio ED
Clin Transplant; 2009; 23(3):351-60. PubMed ID: 19208105
[TBL] [Abstract][Full Text] [Related]
16. Understanding the genetic basis for adverse drug effects: the calcineurin inhibitors.
Bai JP; Lesko LJ; Burckart GJ
Pharmacotherapy; 2010 Feb; 30(2):195-209. PubMed ID: 20099993
[TBL] [Abstract][Full Text] [Related]
17. A numerical scale comparison of renal transplant recipient experience with and opinions about calcineurin inhibitors.
Prasad GV; Nash MM; McFarlane PA; Zaltzman JS
Nephron Clin Pract; 2004; 97(2):c35-40. PubMed ID: 15218328
[TBL] [Abstract][Full Text] [Related]
18. Paired kidney analysis of tacrolimus and cyclosporine microemulsion-based therapy in Chinese cadaveric renal transplant recipients.
Cheung CY; Wong KM; Chan HW; Liu YL; Chan YH; Wong HS; Chak WL; Choi KS; Chau KF; Li CS
Transpl Int; 2006 Aug; 19(8):657-66. PubMed ID: 16827683
[TBL] [Abstract][Full Text] [Related]
19. The CARI guidelines. Calcineurin inhibitors in renal transplantation: adverse effects.
Jose M;
Nephrology (Carlton); 2007 Feb; 12 Suppl 1():S66-74. PubMed ID: 17316284
[No Abstract] [Full Text] [Related]
20. Everolimus with reduced calcineurin inhibitor in thoracic transplant recipients with renal dysfunction: a multicenter, randomized trial.
Gullestad L; Iversen M; Mortensen SA; Eiskjaer H; Riise GC; Mared L; Bjørtuft O; Ekmehag B; Jansson K; Simonsen S; Gude E; Rundqvist B; Fagertun HE; Solbu D; Bergh CH
Transplantation; 2010 Apr; 89(7):864-72. PubMed ID: 20061999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
